Global Community

Gilead leans on a steady HIV business while it pushes hard into cancer and immune diseases with new medicines and a deal-driven pipeline. The big question is whether these launches and approvals can outweigh the near-term bumps from buying and integrating new assets.Read more

Ceres builds and buys digital businesses, and the market may be overlooking that track record because its past ties to cryptocurrency grab the attention. The company is now recycling money from a recent sale into new deals and growth plans tied to its points rewards platform and online brands.Read more

Investment Memo – argenx SE 1. Executive Summary argenx is a commercial-stage biotech in immunology with an active blockbuster (VYVGART) and an advanced pipeline focused on rare autoimmune diseases.Read more

Exceptional investments are often hiding behind familiar labels. Hotel101 Global Holdings may appear, at first glance, to be just another hotel company.Read more

As quantum computing advances from theoretical promise toward practical capability, it introduces a paradox: the same computational power that could unlock breakthroughs in materials science, medicine, and AI also threatens the cryptographic foundations of today’s digital world. Current encryption systems—securing financial transactions, government communications, cloud infrastructure, and digital assets—are fundamentally vulnerable to sufficiently powerful quantum computers.Read more

Below is a professional investment memo (buy-side style) on FTAI Aviation Ltd. , built primarily from investor relations materials (IR site, filings, earnings summaries) and then stress‑tested with broader public information to evaluate strengths, risks, competition, and structural/geopolitical exposure.Read more

Below is a structured Investment Memo for Joint Stock Company Kaspi.kz , based primarily on official Investor Relations financial information and supporting official disclosures. This is followed by a SWOT (DAFO) analysis with referenced insights.Read more

Signature Alliance Group Berhad (SAG) delivered a resilient first quarter performance for FY2026, supported by stronger profit margins, solid operational execution and a healthy order book that continues to provide earnings visibility moving forward. For the quarter ended 31 March 2026, the group posted a net profit of RM8.5 million.Read more

Q3 FY3/26 results update Growth momentum maintained – We view Q1-3 FY3/26 results exemplified another solid quarter at JES, as the company showed sustained double-digit topline and earnings growth YoY. JES demonstrated that despite the sales mix shift toward the Modernization segment, overall returns remained robust, driven by price revision and improved productivity.Read more